The role of Rezūm ™ team ablation of the prostate in the treatment of patients with acute urinary retention secondary to benign prostatic hyperplasia. A single center, single surgeon case series and literature review

Figures & data

Figure 1. Rezūm™ device. Image taken from Boston Scientific.

Figure 2. Relative energy of water. Picture taken from Boston Scientific.

Figure 3. Uniquely contained within prostate anatomy. Images from Michael Hoey, Ph.D. Chief Technology Officer, NxThera Inc. Rezum Pilot Study.

Table 1. Pre-operative data.

Parameter	Mean	Range	Number of patients
Age	74.9	69–97	10
Tamsulosin	n/a	n/a	6
Finasteride	n/a	n/a	0
Combination	n/a	n/a	4
PSA value (ng/mL)	6.1	3.1–12	10
Residual volume (mL)	1100	600–2100	10
TRUS volume (cc)	73.8	64–100	10
IIEF sexual function	37.5	11–64	2

Table 2. Intra-operative data.

Parameter	Mean	Range	Number of patients
Operation time (min)	8.8	5–12	10
Theatre time (min)	29.4	20–31	10
Time in hospital (hour)	5.8	5–18	10
Middle lobe	n/a	n/a	6
Number of cycles	10.3	8–14	10

Table 3. Post-operative data.

Parameter	Mean	Range	Number of patients
Passed TWOC 1 (4 weeks)	n/a	n/a	7
Passed TWOC 2 (6 weeks)	n/a	n/a	3
IPSS	4.5	2–7	10
QoL	0.7	0–3	10
QMAX	13.7	8–19	10
Post void residual (PVR)	107.2	23–169	10

Table 4. Pre and post intervention [Mean follow up period = 7.2 months].

Parameter	Mean value before	Mean value after	Number of patients
BPH medications	10	0	10
Passed TWOC	0	10	10
PSA value (ng/mL)	6.1	2.9	10
TRUS volume (cc)	73.8	41.5	10
IIEF sexual function	37.5	41	2

Figure 4. Clinically significant tissue volume reduction. Image taken from Rezum II Pivotal study Patient. Consent from in study. 2013 07-29 ICF Rev 02 Pivotal.

Figure 5. Sustained durability from 4 year data (Rezum II Pivotal Study) [36–38].